在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。...
Due to the small number of prospective Minimal Residual Disease (MRD) driven studies, the MRD role in AML risk stratification is not clearly defined.The aim of this study was to evaluate the effect of MRD in a real-life setting. We retrospectively analyzed 124 patients with Favorable (FAV) ...
Min-Yen Lo,et al. Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia.Am J He...
在本次大会上,一项题为“Validation of the 2022 European Leukemianet Risk Stratification of Acute Myeloid Leukemia(2022年欧洲白血病网(ELN)急性髓系白血病(AML)风险分层的验证)”的研究入选壁报展示(P4310),为AML风险分层带来重要启示。本期特整理如下,供大家提前阅览。 研究简介 背景 AML在临床结局和疾病生物学...
2022_ELN_Favorable_Code.Rmd R code for replicating results in Archer et al., "Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia" hdcuremodels The hdcuremodels R package was used for fitting high-dimensional mixture cure models. A vignett...
Biomarker Research https://doi.org/10.1186/s40364-020-00208-1 (2020) 8:29 RESEARCH Open Access AML risk stratification models utilizing ELN- 2017 guidelines and additional prognostic factors: a SWOG report Era L. Pogosova-Agadjanyan1, Anna Moseley2, Megan Othus2, Frederick R. Appelbaum1,3...
We performed a post hoc analysis of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) AML1310 trial to investigate the applicability of the ELN2017 risk stratification to our study population. In this trial, after induction and consolidation, patients in complete remission were to ...
ELN2022 risk at diagnosis is associated with the cumulative incidence of relapse/progression (CIR), event-free survival (EFS), and overall survival (OS) in the whole patient cohort, as well as the subgroup of patients transplanted in first remission. However, the risk stratification based on ...
Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapydoi:10.1182/bloodadvances.2024013685Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with...
Additionally, new categories, such as AML with mutated TP53 and MDS/AML, were introduced. ELN 2022 guidelines retained risk stratification approach and emphasized the critical role of measurable residual disease (MRD) that increased the use of next-generation sequencing (NGS) and flow cytom...